comparemela.com

Latest Breaking News On - Kostas biliouris - Page 2 : comparemela.com

Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript

SRPT earnings call for the period ending December 31, 2023.

United statesKristen kluskaDanielle brillGil blum needhamTazeen ahmadBrian skorneyDavid hoangGil blumGena wangWilliam blairKostas biliourisDavid hoang citiIan estepanBrian abrahamsMille cantor fitzgeraldLouise rodino klapac

Alnylam Pharmaceuticals, Inc (NASDAQ:ALNY) Q4 2023 Earnings Call Transcript

Alnylam Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-1.1, expectations were $-1.2.

United statesChristine lindenboomPushkal gargKostas biliourisEllie merleAkshay vaishnawJeff poultonPaul matteisYvonne greenstreetTolga tangulerFastest growing companiesAlnylam pharmaceuticals incCorporate communications at alnylamAlnylam pharmaceuticalsCall transcript februarySenior vice president

Why Alnylam Pharmaceuticals Stock Is Sinking Today

Alnylam's change to a key clinical trial design appears to have worried investors more than a small Q4 revenue miss.

Kostas biliourisAlnylam pharmaceuticalsWall streetMotley fool stock advisorStock advisorLnylam stockStatistical analysis plan

Why Alnylam Pharmaceuticals Stock Is Sinking Today

Alnylam's change to a key clinical trial design appears to have worried investors more than a small Q4 revenue miss.

Kostas biliourisAlnylam pharmaceuticalsWall street

4D Molecular Therapeutics 4D-150 Phase 2 Data Met Investor Expectations, Analyst Boosts Forecast - 4D Molecular Therapeutics (NASDAQ:FDMT)

4D Molecular Therapeutics' 4D-150 Phase 2 results for wet AMD treatment. BMO Capital optimistic, target price raised to $70.

Kostas biliourisRegeneron pharmaceutical incMolecular therapeuticAge related macularMolecular therapeutics

vimarsana © 2020. All Rights Reserved.